Karolinska Development’s portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US
GlobeNewswire·2025-05-13 10:45
STOCKHOLM, SWEDEN, May 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has reached a new milestone with 10,000 patients treated with the innovative nanosynthetic bone graft OssDsign Catalyst on the US market. OssDsign Catalyst is a nanosynthetic bone graft that demonstrates rapid and robust bone formation, even in poorly vascularized environments. Launched in the US in August 2021, OssDsign Catalyst has since achieved significant success in the Amer ...